Heart failure & cardiomyopathiesRandomised controlled trial
Angiotensin-Neprilysin Inhibition and Left Ventricular Assist Device Therapy
- Randomised controlled trial
- multicentre
- open-label
- prospective
Authors' conclusion
ENVAD-HF, a prospective randomized controlled trial of angiotensin-neprilysin inhibition in stable HeartMate 3 LVAD recipients, demonstrated the safety and tolerability of this therapy in this unique population.
Study context
- Population
- Stable HeartMate 3 left ventricular assist device (LVAD) recipients (mean arterial pressure goal 75–90 mm Hg)30 per arm
- Participants
- 60 participants
- Comparison
- Sacubitril/valsartan vs standard of care for managing blood pressure (BP)
- Sacubitril/valsartann = 30
- SOCn = 30reference
- Primary endpoint
- Time to death, deterioration in renal function, hyperkalemia, or symptomatic hypotension leading to drug withdrawal
- Follow-up
- 12 months
Primary result
As reported in the abstract
Hazard ratio
0.42
95% CI 0.08–2.18
P = 0.30
Events by treatment group
Sacubitril/valsartan
2
events
SOC
5
events
Sacubitril/valsartan vs SOC
HR 0.42 (95% CI 0.08–2.18); P = 0.30
Further findings
| Outcome | difference (95% CI) | P value | |
|---|---|---|---|
| Number of BP medications (exploratory) | −1.09 (−1.52 to −0.66) | P < 0.0001 | |
| −2−101Difference (linear scale) |
| Outcome | improvement (95% CI) | P value |
|---|---|---|
| KCCQ-Overall Summary Score (exploratory) | +10.6 (2.6–18.7) | P = 0.011 |
Original publication
Angiotensin-Neprilysin Inhibition and Left Ventricular Assist Device Therapy. JACC Heart Fail. Published 31 August 2025. doi:10.1016/j.jchf.2025.102657
Summarised from the published abstract; every number is checked against it